Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient.
Thrombotic microangiopathy (TMA) in renal transplantation (RTX) generally develops during treatment with calcineurin inhibitors. We present a RTX case that developed TMA under everolimus treatment. A 40-year-old woman received a kidney allograft from her 77-year-old mother. She initially received tacrolimus, mycophenolate mofetil and steroids. She was discharged with a creatinine level of 2.2 mg/dl after treatment for a cellular rejection attack within the first two weeks after transplantation. Later on, tacrolimus was replaced with everolimus. One year later, she presented with fever and increased creatinine level (4 mg/dl), anemia and thrombocytopenia. Her peripheral blood smear revealed signs of microangiopathic hemolysis. Bone marrow examination revealed an increased number of megakaryocytes. We diagnosed the case as TMA and initiated plasma exchange, I.V. pulse steroid treatment and stopped everolimus. This approach improved laboratory and clinic abnormalities. The development of TMA after treatment with everolimus and the exclusion of other possible causes suggested TMA associated with proliferating signal inhibitors (PSIs) in our case.
Yılmaz
Vural Taner
VT
Akdeniz University Hospital, Antalya, Turkey. vuraltaneryl@yahoo.com.tr
Koçak
Hüseyin
H
Avcı
Ali B
AB
Salim
Ozan
O
Ersoy
Fevzi F
FF
Süleymanlar
Gültekin
G
D000328:Adult; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*
D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus